GFP/Luc Reporter Cell Line - MAHLAVU

The Mahlavu cell line is a highly aggressive, well-characterized human model of hepatocellular carcinoma (HCC), originally derived from a primary liver tumor of a female patient. It is particularly distinguished in hepatic oncology by its mesenchymal-like phenotype, mutant p53 status, and exceptional invasive capacity, making it a critical preclinical tool for studying advanced liver cancer, epithelial-mesenchymal transition (EMT), and metastasis. The GFP/Luc Reporter Cell Line - Mahlavu is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct guarantees consistent, high-level expression of both reporter genes across sequential in vitro passages. Importantly, this stable genetic integration is achieved while rigorously preserving the fundamental biological properties, aggressive growth kinetics, and intrinsic tumorigenic potential of the original parental Mahlavu cells.

The incorporation of this dual-reporter system significantly expands the analytical capabilities of the Mahlavu model for comprehensive translational liver cancer research. In vitro, the distinct GFP tag enables researchers to easily monitor cellular morphology, quantify rapid proliferation rates, and isolate specific subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo studies, the strong luciferase expression provides the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and metastatic spread through bioluminescence imaging (BLI). Because it is a human-derived cell line, the Mahlavu-GFP/Luc model is typically engrafted into immunocompromised mice (such as NSG or athymic nude models) to establish highly invasive orthotopic liver models or systemic xenografts. This specialized reporter line serves as an indispensable platform for evaluating the therapeutic efficacy of novel targeted pharmacological compounds, anti-angiogenic agents, and emerging treatments aimed at refractory HCC, facilitating the real-time, accurate quantification of tumor burden in living subjects.